IOmet Readies ID01 And TDO Immuno-Oncology Pipeline For 2016 Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
As IDO inhibitors enter center stage in immune-oncology, the small Scottish start-up IOmet Pharma is busily preparing its cutting edge assets for preclinical studies, which the biotech believes will prove to be best-in-class and perhaps attract eager suitors.